Work

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

Year: 2026

Type: article

Source: The Lancet. Gastroenterology & hepatology

DOI: 10.1016/s2468-1253(26)00263-3

Authors: Mazen Noureddin, Naim Alkhouri, Rohit Loomba, Naga Chalasani, Muhammad Y Sheikh, Shaheen Tomah, Julio A Gutierrez, Silvia Urbina, John J Suschak, Jay Yang, Rachel Garner, M Scot Roberts, Sarah K Browne, Christophe Arbet-Engels, M Scott Harris

Institutions: Methodist Hospital, University of California San Diego, Indiana University School of Medicine, Altimmune (United States)

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7225818403

FWCI:

Cites: 29

Cited by:

Related to: